trending Market Intelligence /marketintelligence/en/news-insights/trending/cukcamtafbclwoba8g4_sw2 content esgSubNav
In This List

Akcea Therapeutics names Ionis exec to its board

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Akcea Therapeutics names Ionis exec to its board

Akcea Therapeutics Inc. named Damien McDevitt to its board.

McDevitt is the chief business officer of Akcea's parent, Ionis Pharmaceuticals Inc. He will replace Stanley Crooke Ionis' founder, chairman and CEO — who has resigned from Akcea's board.

Before joining Ionis in June, McDevitt was senior vice president of corporate development at Acadia Pharmaceuticals Inc. He had also served in various global and strategic business roles at GlaxoSmithKline PLC.

Cambridge, Mass.-based Akcea Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases.